{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T14:15:52Z","timestamp":1794320152971,"version":"4.9.0"},"reference-count":350,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.eprac.2025.07.017","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:15:52Z","timestamp":1758068152000},"page":"1351-1394","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":156,"title":["American Association of Clinical Endocrinology Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity\/Adiposity-Based Chronic Disease \u2013 2025 Update"],"prefix":"10.1016","volume":"31","author":[{"given":"Karl","family":"Nadolsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Timothy","family":"Garvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Bonnecaze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartolome","family":"Burguera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle DeGeeter","family":"Chaplin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcio L.","family":"Griebeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha R.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey N.","family":"Schellinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Simonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reshmi","family":"Srinath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volkan","family":"Yumuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.eprac.2025.07.017_bib1","first-page":"162","article-title":"AACE\/ACE position statement on the prevention, diagnosis, and treatment of obesity","volume":"3","year":"1997","journal-title":"Endocr Pract"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.017_bib2","first-page":"297","article-title":"AACE\/ACE position statement on the prevention, diagnosis, and treatment of obesity","volume":"4","year":"1998","journal-title":"Endocr Pract"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.017_bib3","doi-asserted-by":"crossref","first-page":"642","DOI":"10.4158\/EP12160.PS","article-title":"American Association of Clinical Endocrinologists\u2019 position statement on obesity and obesity medicine","volume":"18","author":"Mechanick","year":"2012","journal-title":"Endocr Pract"},{"issue":"9","key":"10.1016\/j.eprac.2025.07.017_bib4","doi-asserted-by":"crossref","first-page":"977","DOI":"10.4158\/EP14280.PS","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease","volume":"20","author":"Garvey","year":"2014","journal-title":"Endocr Pract"},{"issue":"Suppl 3","key":"10.1016\/j.eprac.2025.07.017_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP161365.GL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive clinical practice guidelines for medical care of patients with obesity","volume":"22","author":"Garvey","year":"2016","journal-title":"Endocr Pract"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.017_bib6","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/ijo.2009.2","article-title":"A proposed clinical staging system for obesity","volume":"33","author":"Sharma","year":"2009","journal-title":"Int J Obes (Lond)"},{"issue":"14","key":"10.1016\/j.eprac.2025.07.017_bib7","doi-asserted-by":"crossref","first-page":"E1059","DOI":"10.1503\/cmaj.110387","article-title":"Using the Edmonton obesity staging system to predict mortality in a population-representative cohort of people with overweight and obesity","volume":"183","author":"Padwal","year":"2011","journal-title":"CMAJ"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.017_bib8","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/oby.20585","article-title":"The progression of cardiometabolic disease: validation of a new cardiometabolic disease staging system applicable to obesity","volume":"22","author":"Guo","year":"2014","journal-title":"Obesity (Silver Spring)"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.017_bib9","doi-asserted-by":"crossref","first-page":"372","DOI":"10.4158\/EP161688.PS","article-title":"Adiposity-based chronic disease as a new diagnostic term: the American Association of Clinical Endocrinologists and American College of Endocrinology position statement","volume":"23","author":"Mechanick","year":"2017","journal-title":"Endocr Pract"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.017_bib10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000497124","article-title":"The ABCD of obesity: an EASO position statement on a diagnostic term with clinical and scientific implications","volume":"12","author":"Fr\u00fchbeck","year":"2019","journal-title":"Obes Facts"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.017_bib11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and diagnostic criteria of clinical obesity","volume":"13","author":"Rubino","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.eprac.2025.07.017_bib12","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/obr.12551","article-title":"Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation","volume":"18","author":"Bray","year":"2017","journal-title":"Obes Rev"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.017_bib13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/oby.22378","article-title":"Obesity as a disease: the Obesity Society 2018 position statement","volume":"27","author":"Jastreboff","year":"2019","journal-title":"Obesity (Silver Spring)"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.017_bib15","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1210\/er.2017-00111","article-title":"Obesity pathogenesis: an Endocrine Society scientific statement","volume":"38","author":"Schwartz","year":"2017","journal-title":"Endocr Rev"},{"issue":"9","key":"10.1016\/j.eprac.2025.07.017_bib16","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13040","article-title":"The biology of human overfeeding: a systematic review","volume":"21","author":"Bray","year":"2020","journal-title":"Obes Rev"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.017_bib17","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41576-021-00414-z","article-title":"The genetics of obesity: from discovery to biology","volume":"23","author":"Loos","year":"2022","journal-title":"Nat Rev Genet"},{"issue":"6","key":"10.1016\/j.eprac.2025.07.017_bib18","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1242\/dmm.008698","article-title":"Set points, settling points and some alternative models: theoretical options to understand how genes and environments combine to regulate body adiposity","volume":"4","author":"Speakman","year":"2011","journal-title":"Dis Model Mech"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.017_bib19","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eprac.2021.11.082","article-title":"Is obesity or adiposity-based chronic disease curable: the set point theory, the environment, and second-generation medications","volume":"28","author":"Garvey","year":"2022","journal-title":"Endocr Pract"},{"key":"10.1016\/j.eprac.2025.07.017_bib20","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.molmet.2017.10.007","article-title":"Why lipostatic set point systems are unlikely to evolve","volume":"7","author":"Speakman","year":"2018","journal-title":"Mol Metab"},{"issue":"Suppl 1 Suppl 1","key":"10.1016\/j.eprac.2025.07.017_bib21","first-page":"S5","article-title":"Physiology of the weight-reduced state: a report from a National Institute of Diabetes and Digestive and Kidney Diseases workshop","volume":"29","author":"Laughlin","year":"2021","journal-title":"Obesity (Silver Spring)"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.017_bib22","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1210\/endrev\/bnab025","article-title":"Arcuate nucleus-dependent regulation of metabolism-pathways to obesity and diabetes mellitus","volume":"43","author":"Jais","year":"2022","journal-title":"Endocr Rev"},{"issue":"10","key":"10.1016\/j.eprac.2025.07.017_bib23","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1038\/s42255-024-01106-8","article-title":"On the pathogenesis of obesity: causal models and missing pieces of the puzzle","volume":"6","author":"Magkos","year":"2024","journal-title":"Nat Metab"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.017_bib24","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41591-020-0803-x","article-title":"Joint international consensus statement for ending stigma of obesity","volume":"26","author":"Rubino","year":"2020","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.eprac.2025.07.017_bib25","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1038\/s41591-024-03095-3","article-title":"A new framework for the diagnosis, staging and management of obesity in adults","volume":"30","author":"Busetto","year":"2024","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.eprac.2025.07.017_bib26","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.eprac.2023.03.272","volume":"29","author":"Nadolsky","year":"2023","journal-title":"Endocr Pract"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.017_bib27","doi-asserted-by":"crossref","first-page":"e1339","DOI":"10.1210\/clinem\/dgab848","article-title":"New horizons. A new paradigm for treating to target with second-generation obesity medications","volume":"107","author":"Garvey","year":"2022","journal-title":"J Clin Endocrinol Metabol"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.017_bib28","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.eprac.2023.02.001","article-title":"American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm - 2023 update","volume":"29","author":"Samson","year":"2023","journal-title":"Endocr Pract"},{"key":"10.1016\/j.eprac.2025.07.017_bib29","first-page":"i","article-title":"Obesity: preventing and managing the global epidemic. Report of a WHO consultation","volume":"894","year":"2000","journal-title":"World Health Organ Tech Rep Ser"},{"issue":"9","key":"10.1016\/j.eprac.2025.07.017_bib30","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1089\/dia.2015.0007","article-title":"Ethnic-specific criteria for classification of body mass index: a perspective for Asian Indians and American Diabetes Association position statement","volume":"17","author":"Misra","year":"2015","journal-title":"Diabetes Technol Ther"},{"issue":"7","key":"10.1016\/j.eprac.2025.07.017_bib31","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S2213-8587(21)00088-7","article-title":"Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: a population-based cohort study","volume":"9","author":"Caleyachetty","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.017_bib32","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00125-022-05803-5","article-title":"Liver, visceral and subcutaneous fat in men and women of South Asian and white European descent: a systematic review and meta-analysis of new and published data","volume":"66","author":"Iliodromiti","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.eprac.2025.07.017_bib33","series-title":"Evidence Review for Accuracy of Anthropometric Measures in Assessing Health Risks Associated with Overweight and Obesity in Adults: Weight Management Suite","year":"2022"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2025.07.017_bib34","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.2337\/dc23-S008","article-title":"8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.017_bib35","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7570\/jomes23031","article-title":"Diagnosis of obesity: 2022 update of clinical practice guidelines for obesity by the Korean Society for the Study of Obesity","volume":"32","author":"Haam","year":"2023","journal-title":"J Obes Metab Syndr"},{"issue":"11","key":"10.1016\/j.eprac.2025.07.017_bib36","first-page":"987","article-title":"Examination Committee of Criteria for \u2018Obesity Disease\u2019 in Japan, Japan Society for the Study of Obesity. New criteria for \u2018obesity disease\u2019 in Japan","volume":"66","year":"2002","journal-title":"Circ J"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.017_bib37","first-page":"83","article-title":"Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults--study on optimal cut-off points of body mass index and waist circumference in Chinese adults","volume":"15","author":"Zhou","year":"2002","journal-title":"Biomed Environ Sci"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.017_bib38","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-65553-9","article-title":"Novel BMI cutoff points for obesity diagnosis in older Hispanic adults","volume":"14","author":"Esparza-Hurtado","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.eprac.2025.07.017_bib39","article-title":"Obesity definition, diagnosis, bias, standard operating procedures (SOPs), and telehealth: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022","volume":"1","author":"Fitch","year":"2022","journal-title":"Obes Pillars"},{"issue":"8","key":"10.1016\/j.eprac.2025.07.017_bib40","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1016\/j.clnu.2019.11.024","article-title":"Critical appraisal of definitions and diagnostic criteria for sarcopenic obesity based on a systematic review","volume":"39","author":"Donini","year":"2020","journal-title":"Clin Nutr"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.017_bib41","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41574-019-0310-7","article-title":"Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity","volume":"16","author":"Ross","year":"2020","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.017_bib42","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13520","article-title":"Obesity in South and Southeast Asia-a new consensus on care and management","volume":"24","author":"Tham","year":"2023","journal-title":"Obes Rev"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.017_bib44","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3945\/ajcn.111.025171","article-title":"Percentage of body fat cutoffs by sex, age, and race-ethnicity in the US adult population from NHANES 1999-2004","volume":"95","author":"Heo","year":"2012","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.017_bib45","doi-asserted-by":"crossref","first-page":"e1103","DOI":"10.1210\/clinem\/dgae341","article-title":"Defining overweight and obesity by percent body fat instead of body mass index","volume":"110","author":"Potter","year":"2025","journal-title":"J Clin Endocrinol Metabol"},{"key":"10.1016\/j.eprac.2025.07.017_bib46","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.2147\/DMSO.S248444","article-title":"Optimal body fat percentage cut-off values in predicting the obesity-related cardiovascular risk factors: a cross-sectional cohort study","volume":"13","author":"Macek","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.eprac.2025.07.017_bib47","article-title":"The role of obesity in sarcopenia and the optimal body composition to prevent against sarcopenia and obesity","volume":"14","author":"Liu","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"10.1016\/j.eprac.2025.07.017_bib48","doi-asserted-by":"crossref","first-page":"bvae164","DOI":"10.1210\/jendso\/bvae164","article-title":"Fundamental body composition principles provide context for fat-free and skeletal muscle loss with GLP-1 RA treatments","volume":"8","author":"Tinsley","year":"2024","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.eprac.2025.07.017_bib49","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/3548284","article-title":"Assessment of body composition in health and disease using bioelectrical impedance analysis (BIA) and dual energy x-ray absorptiometry (DXA): a critical overview","volume":"2019","author":"Marra","year":"2019","journal-title":"Contrast Media Mol Imaging"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.017_bib50","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.3390\/nu13051620","article-title":"Assessment of body composition in athletes: a narrative review of available methods with special reference to quantitative and qualitative bioimpedance analysis","volume":"13","author":"Campa","year":"2021","journal-title":"Nutrients"},{"issue":"Suppl 2","key":"10.1016\/j.eprac.2025.07.017_bib51","article-title":"Diagnosis of obesity based on body composition-associated health risks-time for a change in paradigm","volume":"22","author":"Bosy-Westphal","year":"2021","journal-title":"Obes Rev"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.017_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097846","article-title":"Reference values for body composition and anthropometric measurements in athletes","volume":"9","author":"Santos","year":"2014","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.017_bib53","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/02601060211002941","article-title":"Simple anthropometry-based calculations to monitor body composition in athletes: scoping review and reference values","volume":"28","author":"Bonilla","year":"2022","journal-title":"Nutr Health"},{"key":"10.1016\/j.eprac.2025.07.017_bib54","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.nut.2018.11.028","article-title":"Current technologies in body composition assessment: advantages and disadvantages","volume":"62","author":"Ceniccola","year":"2019","journal-title":"Nutrition"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.017_bib55","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41430-018-0335-3","article-title":"Bioelectrical impedance analysis for body composition assessment: reflections on accuracy, clinical utility, and standardisation","volume":"73","author":"Ward","year":"2019","journal-title":"Eur J Clin Nutr"},{"issue":"12","key":"10.1016\/j.eprac.2025.07.017_bib56","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13127","article-title":"Metabolically healthy overweight\/obesity are associated with increased risk of cardiovascular disease in adults, even in the absence of metabolic risk factors: a systematic review and meta-analysis of prospective cohort studies","volume":"21","author":"Opio","year":"2020","journal-title":"Obes Rev"},{"issue":"9612","key":"10.1016\/j.eprac.2025.07.017_bib57","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0140-6736(08)60269-X","article-title":"Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies","volume":"371","author":"Renehan","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.017_bib58","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/oby.21801","article-title":"Redefining obesity: beyond the numbers","volume":"25","author":"Sharma","year":"2017","journal-title":"Obesity (Silver Spring)"},{"issue":"7","key":"10.1016\/j.eprac.2025.07.017_bib59","doi-asserted-by":"crossref","first-page":"856","DOI":"10.2337\/dc17-0088","article-title":"Cardiometabolic disease staging predicts effectiveness of weight-loss therapy to prevent type 2 diabetes: pooled results from phase III clinical trials assessing phentermine\/topiramate extended release","volume":"40","author":"Guo","year":"2017","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.eprac.2025.07.017_bib60","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13120","article-title":"Usefulness of the Edmonton Obesity Staging System for stratifying the presence and severity of weight-related health problems in clinical and community settings: a rapid review of observational studies","volume":"21","author":"Atlantis","year":"2020","journal-title":"Obes Rev"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.017_bib61","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1007\/s11695-023-06516-3","article-title":"Beyond the BMI: a critical analysis of the Edmonton Obesity Staging System and the new guidelines for indications for metabolic and bariatric surgery","volume":"33","author":"Pajecki","year":"2023","journal-title":"Obes Surg"},{"issue":"8","key":"10.1016\/j.eprac.2025.07.017_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003232","article-title":"Development and validation of a model for predicting incident type 2 diabetes using quantitative clinical data and a Bayesian logistic model: a nationwide cohort and modeling study","volume":"17","author":"Wilkinson","year":"2020","journal-title":"PLoS Med"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.017_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.100868","article-title":"Cardiometabolic disease staging and major adverse cardiovascular event prediction in 2 prospective cohorts","volume":"3","author":"Howell","year":"2024","journal-title":"JACC Adv"},{"issue":"7","key":"10.1016\/j.eprac.2025.07.017_bib64","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11892-023-01510-6","article-title":"Sleep apnea, obesity, and diabetes - an intertwined trio","volume":"23","author":"Kurnool","year":"2023","journal-title":"Curr Diab Rep"},{"issue":"8","key":"10.1016\/j.eprac.2025.07.017_bib65","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1002\/art.39707","article-title":"Association between overweight and obesity and risk of clinically diagnosed knee, hip, and hand osteoarthritis: a population-based cohort study","volume":"68","author":"Reyes","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.017_bib66","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.017_bib67","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.017_bib68","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1159\/000539371","article-title":"European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"17","year":"2024","journal-title":"Obes Facts"},{"issue":"11","key":"10.1016\/j.eprac.2025.07.017_bib69","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1007\/s00125-024-06196-3","article-title":"European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): executive summary","volume":"67","year":"2024","journal-title":"Diabetologia"},{"issue":"1 Suppl 1","key":"10.1016\/j.eprac.2025.07.017_bib70","first-page":"S27","article-title":"2. Diagnosis and classification of diabetes: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.017_bib71","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000445061","article-title":"Rare genetic forms of obesity: clinical approach and current treatments in 2016","volume":"9","author":"Huvenne","year":"2016","journal-title":"Obes Facts"},{"issue":"11","key":"10.1016\/j.eprac.2025.07.017_bib72","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.1007\/s00431-023-05159-x","article-title":"Rare genetic forms of obesity in childhood and adolescence, a comprehensive review of their molecular mechanisms and diagnostic approach","volume":"182","author":"Mainieri","year":"2023","journal-title":"Eur J Pediatr"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.017_bib73","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1210\/jc.2014-3415","article-title":"Pharmacological management of obesity: an endocrine Society clinical practice guideline","volume":"100","author":"Apovian","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.017_bib74","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2337\/dci19-0014","article-title":"Nutrition therapy for adults with diabetes or prediabetes: a consensus report","volume":"42","author":"Evert","year":"2019","journal-title":"Diabetes Care"},{"issue":"10077","key":"10.1016\/j.eprac.2025.07.017_bib75","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial","volume":"389","author":"le Roux","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.017_bib76","doi-asserted-by":"crossref","first-page":"912","DOI":"10.2337\/dc13-1518","article-title":"Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release","volume":"37","author":"Garvey","year":"2014","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.eprac.2025.07.017_bib77","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.2337\/dc06-0560","article-title":"Effect of weight loss with lifestyle intervention on risk of diabetes","volume":"29","author":"Hamman","year":"2006","journal-title":"Diabetes care"},{"issue":"12","key":"10.1016\/j.eprac.2025.07.017_bib78","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-8587(14)70214-1","article-title":"Incidence of type 2 diabetes after bariatric surgery: population-based matched cohort study","volume":"2","author":"Booth","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2025.07.017_bib79","first-page":"S113","article-title":"8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of medical care in diabetes-2022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes care"},{"issue":"7","key":"10.1016\/j.eprac.2025.07.017_bib80","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.2337\/dc17-2222","article-title":"Global diabetes prevention interventions: a systematic review and network meta-analysis of the real-world impact on incidence, weight, and glucose","volume":"41","author":"Galaviz","year":"2018","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.eprac.2025.07.017_bib81","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.eprac.2022.08.002","article-title":"American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan\u20142022 update","volume":"28","author":"Blonde","year":"2022","journal-title":"Endocr Pract"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.017_bib82","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S2213-8587(24)00346-2","article-title":"Impact of bodyweight loss on type 2 diabetes remission: a systematic review and meta-regression analysis of randomised controlled trials","volume":"13","author":"Kanbour","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10120","key":"10.1016\/j.eprac.2025.07.017_bib83","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(17)33102-1","article-title":"Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial","volume":"391","author":"Lean","year":"2018","journal-title":"Lancet (London, England)"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.017_bib84","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00125-016-3903-x","article-title":"Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomised controlled trial","volume":"59","author":"Cummings","year":"2016","journal-title":"Diabetologia"},{"issue":"11","key":"10.1016\/j.eprac.2025.07.017_bib85","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of Hyperglycemia in Type 2 Diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.eprac.2025.07.017_bib86","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc10-2415","article-title":"Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes","volume":"34","author":"Wing","year":"2011","journal-title":"Diabetes care"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.017_bib87","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1177\/0145721712443293","article-title":"Association between glycosylated hemoglobin and intentional weight loss in overweight and obese patients with type 2 diabetes mellitus: a retrospective cohort study","volume":"38","author":"Shantha","year":"2012","journal-title":"Diabetes Educ"},{"issue":"11","key":"10.1016\/j.eprac.2025.07.017_bib88","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S2213-8587(16)30162-0","article-title":"Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial","volume":"4","author":"Gregg","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.eprac.2025.07.017_bib89","doi-asserted-by":"crossref","DOI":"10.1111\/dme.14395","article-title":"Predictors of type 2 diabetes remission in the Diabetes Remission Clinical Trial (DiRECT)","volume":"38","author":"Thom","year":"2021","journal-title":"Diabetic Med"},{"issue":"Supplement_1","key":"10.1016\/j.eprac.2025.07.017_bib90","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.2337\/dc25-S008","article-title":"8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.eprac.2025.07.017_bib91","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.2337\/dc21-0166","article-title":"Prognostic models for predicting remission of diabetes following bariatric surgery: a systematic review and meta-analysis","volume":"44","author":"Singh","year":"2021","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.017_bib92","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S2213-8587(19)30068-3","article-title":"Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial","volume":"7","author":"Lean","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.017_bib93","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/HYP.0000000000000202","article-title":"Weight-loss strategies for prevention and treatment of hypertension: a scientific statement from the American Heart Association","volume":"78","author":"Hall","year":"2021","journal-title":"Hypertension"},{"issue":"7","key":"10.1016\/j.eprac.2025.07.017_bib94","doi-asserted-by":"crossref","DOI":"10.3390\/nu11071667","article-title":"Weight loss and hypertension in obese subjects","volume":"11","author":"Fantin","year":"2019","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.017_bib95","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.eprac.2025.07.017_bib96","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.4158\/CS-2020-0490","article-title":"Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm - 2020 executive summary","volume":"26","author":"Handelsman","year":"2020","journal-title":"Endocr Pract"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.017_bib97","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.eprac.2025.07.017_bib98","article-title":"Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content: systematic review and network meta-analysis","author":"Koh","year":"2024","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.eprac.2025.07.017_bib99","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1007\/s11695-024-07585-8","article-title":"Metabolic-associated fatty liver disease and weight loss after bariatric surgery: a systematic review and meta-analysis","volume":"34","author":"Sabench","year":"2024","journal-title":"Obes Surg"},{"issue":"12","key":"10.1016\/j.eprac.2025.07.017_bib100","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"11-12","key":"10.1016\/j.eprac.2025.07.017_bib101","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1111\/apt.18331","article-title":"Semaglutide 2.4 mg in participants with metabolic dysfunction-associated steatohepatitis: baseline characteristics and design of the phase 3 ESSENCE trial","volume":"60","author":"Newsome","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.017_bib102","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.017_bib103","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.gastro.2020.11.051","article-title":"Clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: Expert review","volume":"160","author":"Younossi","year":"2021","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.017_bib104","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.017_bib105","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12902-022-00980-1","article-title":"Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss","volume":"22","author":"Pouwels","year":"2022","journal-title":"BMC Endocr Disord"},{"issue":"11","key":"10.1016\/j.eprac.2025.07.017_bib106","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.5665\/sleep.2204","article-title":"A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine\/topiramate for the treatment of obstructive sleep apnea in obese adults","volume":"35","author":"Winslow","year":"2012","journal-title":"Sleep"},{"key":"10.1016\/j.eprac.2025.07.017_bib107","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.sleep.2024.06.014","article-title":"Weight reduction and the impact on apnea-hypopnea index: A systematic meta-analysis","volume":"121","author":"Malhotra","year":"2024","journal-title":"Sleep Med"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.017_bib108","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.5664\/jcsm.9834","article-title":"Dose-response relationship between weight loss and improvements in obstructive sleep apnea severity after a diet\/lifestyle interventions: secondary analyses of the \u201cMIMOSA\u201d randomized clinical trial","volume":"18","author":"Georgoulis","year":"2022","journal-title":"J Clin Sleep Med"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.017_bib109","doi-asserted-by":"crossref","first-page":"641","DOI":"10.5665\/sleep.2618","article-title":"Long-term effect of weight loss on obstructive sleep apnea severity in obese patients with type 2 diabetes","volume":"36","author":"Kuna","year":"2013","journal-title":"Sleep"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.017_bib110","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa0806375","article-title":"Weight loss to treat urinary incontinence in overweight and obese women","volume":"360","author":"Subak","year":"2009","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.eprac.2025.07.017_bib111","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/obr.12170","article-title":"The effect of non-surgical weight loss interventions on urinary incontinence in overweight women: a systematic review and meta-analysis","volume":"15","author":"Vissers","year":"2014","journal-title":"Obes Rev"},{"issue":"25","key":"10.1016\/j.eprac.2025.07.017_bib112","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1056\/NEJMcp1914037","article-title":"Stress incontinence in women","volume":"384","author":"Wu","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.eprac.2025.07.017_bib113","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s00192-018-03865-x","article-title":"The impact of bariatric surgery on urinary incontinence: a systematic review and meta-analysis","volume":"30","author":"Purwar","year":"2019","journal-title":"Int Urogynecol J"},{"issue":"14","key":"10.1016\/j.eprac.2025.07.017_bib114","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1001\/jama.2021.1438","article-title":"Review of gastroesophageal reflux disease","volume":"325","author":"Mehta","year":"2021","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.eprac.2025.07.017_bib115","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/j.cgh.2015.05.034","article-title":"Weight loss is truly effective in reducing symptoms and proton pump inhibitor use in patients with gastroesophageal reflux disease","volume":"13","author":"De Bortoli","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.017_bib116","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.cgh.2015.04.176","article-title":"Lifestyle intervention in gastroesophageal reflux disease","volume":"14","author":"Ness-Jensen","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.017_bib117","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s11695-015-1902-5","article-title":"The impact of bariatric surgery on polycystic ovary syndrome: A systematic review and meta-analysis","volume":"26","author":"Skubleny","year":"2016","journal-title":"Obes Surg"},{"key":"10.1016\/j.eprac.2025.07.017_bib118","doi-asserted-by":"crossref","first-page":"848947","DOI":"10.3389\/fendo.2022.848947","article-title":"Metabolic surgery on patients with polycystic ovary syndrome: A systematic review and meta-Analysis","volume":"13","author":"Yue","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"10.1016\/j.eprac.2025.07.017_bib119","doi-asserted-by":"crossref","first-page":"101894","DOI":"10.1016\/j.jogoh.2020.101894","article-title":"Implementing the international evidence-based guideline of assessment and management of polycystic ovary syndrome (PCOS): how to achieve weight loss in overweight and obese women with PCOS?","volume":"50","author":"Lie Fong","year":"2021","journal-title":"J Gynecol Obstet Hum Reprod"},{"issue":"9","key":"10.1016\/j.eprac.2025.07.017_bib120","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S2213-8587(22)00163-2","article-title":"Polycystic ovary syndrome","volume":"10","author":"Joham","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.017_bib121","doi-asserted-by":"crossref","first-page":"e1071","DOI":"10.1210\/clinem\/dgaa839","article-title":"Update on PCOS: consequences, challenges, and guiding treatment","volume":"106","author":"Hoeger","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.017_bib122","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/cen.14726","article-title":"How to manage weight loss in women with obesity and PCOS seeking fertility?","volume":"97","author":"Hazlehurst","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"9","key":"10.1016\/j.eprac.2025.07.017_bib123","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/oby.22936","article-title":"Intensive weight loss intervention and cancer risk in adults with type 2 diabetes: analysis of the Look AHEAD Randomized Clinical Trial","volume":"28","author":"Yeh","year":"2020","journal-title":"Obesity (Silver SpringMd)"},{"issue":"9","key":"10.1016\/j.eprac.2025.07.017_bib124","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1136\/ijgc-2019-000728","article-title":"Intentional weight loss, weight cycling, and endometrial cancer risk: a systematic review and meta-analysis","volume":"29","author":"Zhang","year":"2019","journal-title":"Int J Gynecol Cancerr"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.017_bib125","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/cncr.31687","article-title":"Weight loss and breast cancer incidence in postmenopausal women","volume":"125","author":"Chlebowski","year":"2019","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.eprac.2025.07.017_bib126","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1097\/SLA.0000000000003331","article-title":"Bariatric surgery is associated with reduced risk of breast cancer in both premenopausal and postmenopausal women","volume":"272","author":"Feigelson","year":"2020","journal-title":"Ann Surg"},{"issue":"9","key":"10.1016\/j.eprac.2025.07.017_bib127","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/jnci\/djz226","article-title":"Sustained weight loss and risk of breast cancer in women 50 years and older: A pooled analysis of prospective data","volume":"112","author":"Teras","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"21","key":"10.1016\/j.eprac.2025.07.017_bib128","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and cardiovascular disease: a scientific statement from the American Heart Association","volume":"143","author":"Powell-Wiley","year":"2021","journal-title":"Circulation"},{"issue":"24","key":"10.1016\/j.eprac.2025.07.017_bib129","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.017_bib130","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1097\/EDE.0000000000001393","article-title":"Weight change and the onset of cardiovascular diseases: Emulating trials using electronic health records","volume":"32","author":"Katsoulis","year":"2021","journal-title":"Epidemiology"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.017_bib131","doi-asserted-by":"crossref","DOI":"10.1111\/cob.12316","article-title":"Obesity in older adults: effect of degree of weight loss on cardiovascular markers and medications","volume":"9","author":"Haywood","year":"2019","journal-title":"Clin Obes"},{"key":"10.1016\/j.eprac.2025.07.017_bib132","doi-asserted-by":"crossref","DOI":"10.15344\/2456-8007\/2019\/131","article-title":"Cardiovascular risk reduction associated with pharmacological weight loss: a meta-analysis","volume":"4","author":"Kane","year":"2019","journal-title":"Int J Clin Res trials"},{"issue":"9","key":"10.1016\/j.eprac.2025.07.017_bib133","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1016\/j.numecd.2021.05.023","article-title":"Effects of weight loss medications on mortality and cardiovascular events: a systematic review of randomized controlled trials in adults with overweight and obesity","volume":"31","author":"Capristo","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"10","key":"10.1016\/j.eprac.2025.07.017_bib134","doi-asserted-by":"crossref","DOI":"10.3390\/nu13103568","article-title":"Reduction of major adverse cardiovascular events (MACE) after bariatric surgery in patients with obesity and cardiovascular diseases: A systematic review and meta-analysis","volume":"13","author":"Sutanto","year":"2021","journal-title":"Nutrients"},{"issue":"8","key":"10.1016\/j.eprac.2025.07.017_bib135","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.soard.2022.05.007","article-title":"Effect of bariatric surgery on long-term cardiovascular outcomes: a systematic review and meta-analysis of population-based cohort studies","volume":"18","author":"Tang","year":"2022","journal-title":"Surg Obes Relat Dis"},{"issue":"11","key":"10.1016\/j.eprac.2025.07.017_bib136","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.2337\/dc20-3023","article-title":"Cardiovascular outcomes in patients with type 2 diabetes and obesity: comparison of gastric bypass, sleeve gastrectomy, and usual care","volume":"44","author":"Aminian","year":"2021","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.017_bib137","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/eurjpc\/zwae279","article-title":"Obesity and cardiovascular disease: an ESC clinical consensus statement","volume":"32","author":"Koskinas","year":"2025","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.017_bib138","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ijcard.2014.02.026","article-title":"Bariatric surgery and its impact on cardiovascular disease and mortality: a systematic review and meta-analysis","volume":"173","author":"Kwok","year":"2014","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.017_bib139","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s13679-017-0262-y","article-title":"Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over","volume":"6","author":"Ryan","year":"2017","journal-title":"Curr Obes Rep"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.017_bib140","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/oby.23371","article-title":"Benefits of weight loss of 10% or more in patients with overweight or obesity: a review","volume":"30","author":"Tahrani","year":"2022","journal-title":"Obesity (Silver Spring)"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.017_bib141","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s12529-010-9092-y","article-title":"The association between rate of initial weight loss and long-term success in obesity treatment: does slow and steady win the race?","volume":"17","author":"Nackers","year":"2010","journal-title":"Int J Behav Med"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.017_bib142","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/obr.12772","article-title":"Determinants of weight loss maintenance: a systematic review","volume":"20","author":"Varkevisser","year":"2019","journal-title":"Obes Rev"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.017_bib143","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13148","article-title":"Predictors of successful weight loss outcomes amongst individuals with obesity undergoing lifestyle interventions: a systematic review","volume":"22","author":"Chopra","year":"2021","journal-title":"Obes Rev"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.017_bib144","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11695-023-06913-8","article-title":"IFSO Consensus on definitions and clinical practice guidelines for obesity management-an International Delphi Study","volume":"34","author":"Salminen","year":"2024","journal-title":"Obes Surg"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.017_bib145","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/oby.21346","article-title":"The effect of rate of weight loss on long-term weight regain in adults with overweight and obesity","volume":"24","author":"Vink","year":"2016","journal-title":"Obesity (Silver Spring)"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2025.07.017_bib146","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/dom.14200","article-title":"Evidence-based weight loss interventions: individualized treatment options to maximize patient outcomes","volume":"23","author":"Bray","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.017_bib147","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s13679-023-00518-z","article-title":"Obesity and dyslipidemia: a review of current evidence","volume":"12","author":"Vekic","year":"2023","journal-title":"Curr Obes Rep"},{"issue":"10","key":"10.1016\/j.eprac.2025.07.017_bib148","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s11886-017-0912-4","article-title":"Hypertension in obesity and the impact of weight loss","volume":"19","author":"Cohen","year":"2017","journal-title":"Curr Cardiol Rep"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.017_bib149","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032395","article-title":"Intentional weight loss and dose reductions of anti-diabetic medications--a retrospective cohort study","volume":"7","author":"Kumar","year":"2012","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.017_bib150","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41366-024-01648-7","article-title":"Comparative effectiveness of metabolic and bariatric surgeries: a network meta-analysis","volume":"49","author":"Malik","year":"2025","journal-title":"Int J Obes (London)"},{"issue":"6","key":"10.1016\/j.eprac.2025.07.017_bib151","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2337\/dc16-0236","article-title":"Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations","volume":"39","author":"Rubino","year":"2016","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.017_bib152","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11695-022-06332-1","article-title":"2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) indications for metabolic and bariatric surgery","volume":"33","author":"Eisenberg","year":"2023","journal-title":"Obes Surg"},{"issue":"11","key":"10.1016\/j.eprac.2025.07.017_bib153","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.soard.2024.05.009","article-title":"Scientific evidence for the updated guidelines on indications for metabolic and bariatric surgery (IFSO\/ASMBS)","volume":"20","author":"De Luca","year":"2024","journal-title":"Surg Obes Relat Dis"},{"issue":"12","key":"10.1016\/j.eprac.2025.07.017_bib154","doi-asserted-by":"crossref","DOI":"10.1093\/bjs\/znae283","article-title":"International consensus position statement on the role of obesity management medications in the context of metabolic bariatric surgery: expert guideline by the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO)","volume":"111","author":"Cohen","year":"2024","journal-title":"Br J Surg"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.017_bib155","doi-asserted-by":"crossref","first-page":"O1","DOI":"10.1002\/oby.22719","volume":"28","author":"Mechanick","year":"2020","journal-title":"Obesity (Silver Spring)"},{"issue":"9","key":"10.1016\/j.eprac.2025.07.017_bib156","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1210\/en.2003-0580","article-title":"Minireview: the adipocyte\u2014at the crossroads of energy homeostasis, inflammation, and atherosclerosis","volume":"144","author":"Rajala","year":"2003","journal-title":"Endocrinology"},{"issue":"13","key":"10.1016\/j.eprac.2025.07.017_bib157","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.3390\/ijms21134759","article-title":"Signaling pathways that control muscle mass","volume":"21","author":"Vainshtein","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.eprac.2025.07.017_bib158","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/S0002-8223(02)90346-9","article-title":"Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids","volume":"102","author":"Trumbo","year":"2002","journal-title":"J Am Diet Assoc"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.017_bib159","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jada.2005.02.005","article-title":"Comparison of predictive equations for resting metabolic rate in healthy nonobese and obese adults: a systematic review","volume":"105","author":"Frankenfield","year":"2005","journal-title":"J Am Diet Assoc"},{"issue":"11","key":"10.1016\/j.eprac.2025.07.017_bib160","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1017\/S000711452000224X","article-title":"Effects of gradual weight loss v. rapid weight loss on body composition and RMR: a systematic review and meta-analysis","volume":"124","author":"Ashtary-Larky","year":"2020","journal-title":"Br J Nutr"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.017_bib161","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/oby.23333","article-title":"Metabolic adaptation delays time to reach weight loss goals","volume":"30","author":"Martins","year":"2022","journal-title":"Obesity (Silver Spring)"},{"issue":"7","key":"10.1016\/j.eprac.2025.07.017_bib162","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1053\/j.gastro.2017.01.052","article-title":"Obesity energetics: body weight regulation and the effects of diet composition","volume":"152","author":"Hall","year":"2017","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.017_bib163","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.clnu.2012.08.016","article-title":"Body composition changes after weight-loss interventions for overweight and obesity","volume":"32","author":"Santarpia","year":"2013","journal-title":"Clin Nutr"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.017_bib164","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000528083","article-title":"European Association for the Study of Obesity position statement on medical nutrition therapy for the management of overweight and obesity in adults developed in collaboration with the European Federation of the Associations of Dietitians","volume":"16","author":"Hassapidou","year":"2023","journal-title":"Obes Facts"},{"issue":"25 Suppl 2","key":"10.1016\/j.eprac.2025.07.017_bib165","first-page":"S102","article-title":"2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society","volume":"129","author":"Jensen","year":"2014","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.017_bib166","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.eprac.2025.07.017_bib167","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Eng J Med"},{"issue":"9774","key":"10.1016\/j.eprac.2025.07.017_bib168","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet"},{"issue":"9741","key":"10.1016\/j.eprac.2025.07.017_bib169","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","article-title":"Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"376","author":"Greenway","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.017_bib170","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/oby.22642","article-title":"Weight history in clinical practice: the state of the science and future directions","volume":"28","author":"Kushner","year":"2020","journal-title":"Obesity (Silver Spring)"},{"issue":"8","key":"10.1016\/j.eprac.2025.07.017_bib171","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1002\/oby.21538","article-title":"Persistent metabolic adaptation 6 years after \u201cThe Biggest Loser\u201d competition","volume":"24","author":"Fothergill","year":"2016","journal-title":"Obesity (Silver Spring)"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.017_bib172","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3945\/an.115.008755","article-title":"Is obesity associated with altered energy expenditure?","volume":"7","author":"Carneiro","year":"2016","journal-title":"Adv Nutr"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.017_bib173","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1745-7599.2007.00220.x","article-title":"Use of bioelectrical impedance analysis in the evaluation, treatment, and prevention of overweight and obesity","volume":"19","author":"Ricciardi","year":"2007","journal-title":"J Am Acad Nurse Pract"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.017_bib175","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.293.1.43","article-title":"Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial","volume":"293","author":"Dansinger","year":"2005","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.eprac.2025.07.017_bib176","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1161\/01.CIR.99.6.779","article-title":"Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study","volume":"99","author":"de Lorgeril","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.eprac.2025.07.017_bib177","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa1200303","article-title":"Retraction and republication: primary prevention of cardiovascular disease with a Mediterranean diet","volume":"368","author":"Estruch","year":"2013","journal-title":"N Engl J Med"},{"issue":"10338","key":"10.1016\/j.eprac.2025.07.017_bib178","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/S0140-6736(22)00122-2","article-title":"Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial","volume":"399","author":"Delgado-Lista","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.017_bib179","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2337\/dc10-1288","article-title":"Reduction in the incidence of type 2 diabetes with the Mediterranean diet: results of the PREDIMED-Reus nutrition intervention randomized trial","volume":"34","author":"Salas-Salvad\u00f3","year":"2011","journal-title":"Diabetes Care"},{"issue":"31","key":"10.1016\/j.eprac.2025.07.017_bib180","doi-asserted-by":"crossref","first-page":"E875","DOI":"10.1503\/cmaj.191707","article-title":"Obesity in adults: a clinical practice guideline","volume":"192","author":"Wharton","year":"2020","journal-title":"CMAJ"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.017_bib181","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2337\/dc18-2270","article-title":"The effect of liquid meal replacements on cardiometabolic risk factors in overweight\/obese individuals with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"42","author":"Noronha","year":"2019","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.017_bib182","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/obr.12816","article-title":"A systematic review and meta-analysis of the effectiveness of meal replacements for weight loss","volume":"20","author":"Astbury","year":"2019","journal-title":"Obes Rev"},{"issue":"8","key":"10.1016\/j.eprac.2025.07.017_bib183","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.jand.2021.05.001","article-title":"The effect of meal replacement on weight loss according to calorie-restriction type and proportion of energy intake: a systematic review and meta-analysis of randomized controlled trials","volume":"121","author":"Min","year":"2021","journal-title":"J Acad Nutr Diet"},{"issue":"9","key":"10.1016\/j.eprac.2025.07.017_bib184","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/oby.23505","article-title":"Impact of program characteristics on weight loss in adult behavioral weight management interventions: systematic review and component network meta-analysis","volume":"30","author":"Hartmann-Boyce","year":"2022","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.017_bib185","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s00125-021-05577-2","article-title":"Diets for weight management in adults with type 2 diabetes: an umbrella review of published meta-analyses and systematic review of trials of diets for diabetes remission","volume":"65","author":"Churuangsuk","year":"2022","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.017_bib186","doi-asserted-by":"crossref","DOI":"10.1016\/j.advnut.2023.10.003","article-title":"Effects of intermittent energy restriction compared with those of continuous energy restriction on body composition and cardiometabolic risk markers - a systematic review and meta-analysis of randomized controlled trials in adults","volume":"15","author":"Schroor","year":"2024","journal-title":"Adv Nutr"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.017_bib187","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Mart\u00ednez","year":"2022","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.017_bib188","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41575-020-00375-4","article-title":"Dietary fibre in gastrointestinal health and disease","volume":"18","author":"Gill","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.017_bib189","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3945\/ajcn.112.047563","article-title":"Contribution of gastroenteropancreatic appetite hormones to protein-induced satiety","volume":"97","author":"Belza","year":"2013","journal-title":"Am J Clin Nutr"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.017_bib190","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/ajcn\/72.5.1135","article-title":"Effect of fat-reduced diets on 24-h energy expenditure: comparisons between animal protein, vegetable protein, and carbohydrate","volume":"72","author":"Mikkelsen","year":"2000","journal-title":"Am J Clin Nutr"},{"issue":"6","key":"10.1016\/j.eprac.2025.07.017_bib191","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.3945\/ajcn.112.044321","article-title":"Effects of energy-restricted high-protein, low-fat compared with standard-protein, low-fat diets: a meta-analysis of randomized controlled trials","volume":"96","author":"Wycherley","year":"2012","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.017_bib192","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/ajcn\/nqaa283","article-title":"A high-protein total diet replacement increases energy expenditure and leads to negative fat balance in healthy, normal-weight adults","volume":"113","author":"Oliveira","year":"2021","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.017_bib193","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1093\/ajcn\/83.2.260","article-title":"Effects of variation in protein and carbohydrate intake on body mass and composition during energy restriction: a meta-regression 1","volume":"83","author":"Krieger","year":"2006","journal-title":"Am J Clin Nutr"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.017_bib194","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/cob.12188","article-title":"Markers of dietary protein intake are associated with successful weight loss in the POUNDS Lost trial","volume":"7","author":"Bray","year":"2017","journal-title":"Clin Obes"},{"key":"10.1016\/j.eprac.2025.07.017_bib195","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12970-017-0177-8","article-title":"International Society of Sports Nutrition position stand: protein and exercise","volume":"14","author":"J\u00e4ger","year":"2017","journal-title":"J Int Soc Sports Nutr"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.017_bib196","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/ehf2.13213","article-title":"High-protein vs. standard-protein diets in overweight and obese patients with heart failure and diabetes mellitus: findings of the Pro-HEART trial","volume":"8","author":"Evangelista","year":"2021","journal-title":"ESC Heart Fail"},{"issue":"3 Suppl 1","key":"10.1016\/j.eprac.2025.07.017_bib197","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.ajkd.2020.05.006","article-title":"KDOQI clinical practice guideline for nutrition in CKD: 2020 Update","volume":"76","author":"Ikizler","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.017_bib198","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.kint.2020.06.024","article-title":"Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment","volume":"98","author":"de Boer","year":"2020","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.017_bib199","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"102","author":"de Boer","year":"2022","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.017_bib200","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1139\/apnm-2022-0131","article-title":"Correction: Protein \u201crequirements\u201d beyond the RDA: implications for optimizing health","volume":"47","author":"Phillips","year":"2022","journal-title":"Appl Physiol Nutr Metab"},{"key":"10.1016\/j.eprac.2025.07.017_bib201","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.clnesp.2024.06.030","article-title":"Enhanced protein intake on maintaining muscle mass, strength, and physical function in adults with overweight\/obesity: a systematic review and meta-analysis","volume":"63","author":"Kokura","year":"2024","journal-title":"Clin Nutr ESPEN"},{"issue":"14","key":"10.1016\/j.eprac.2025.07.017_bib202","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1056\/NEJMra2214275","article-title":"Guidance on energy and macronutrients across the life span","volume":"390","author":"Heymsfield","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.017_bib203","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1039\/C5FO01530H","article-title":"Dietary protein intake and human health","volume":"7","author":"Wu","year":"2016","journal-title":"Food Funct"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.017_bib204","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1249\/MSS.0b013e3181949333","article-title":"Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults","volume":"41","author":"Donnelly","year":"2009","journal-title":"Med Sci Sports Exerc"},{"issue":"7","key":"10.1016\/j.eprac.2025.07.017_bib205","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s12603-021-1665-8","article-title":"International Exercise Recommendations in Older Adults (ICFSR): expert consensus guidelines","volume":"25","author":"Izquierdo","year":"2021","journal-title":"J Nutr Health Aging"},{"issue":"17","key":"10.1016\/j.eprac.2025.07.017_bib206","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1093\/eurjpc\/zwac187","article-title":"Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation","volume":"29","author":"Lopez-Jimenez","year":"2022","journal-title":"Eur J Prev Cardiol"},{"issue":"Suppl 4 Suppl 4","key":"10.1016\/j.eprac.2025.07.017_bib207","article-title":"Exercise training in the management of overweight and obesity in adults: synthesis of the evidence and recommendations from the European Association for the Study of Obesity Physical Activity Working Group","volume":"22","author":"Oppert","year":"2021","journal-title":"Obes Rev"},{"issue":"6","key":"10.1016\/j.eprac.2025.07.017_bib208","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1249\/MSS.0000000000001938","article-title":"Physical activity and the prevention of weight gain in adults: a systematic review","volume":"51","author":"Jakicic","year":"2019","journal-title":"Med Sci Sports Exerc"},{"issue":"12","key":"10.1016\/j.eprac.2025.07.017_bib209","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1007\/s40279-023-01899-w","article-title":"Effect of soy protein supplementation on muscle adaptations, metabolic and antioxidant status, hormonal response, and exercise performance of active individuals and athletes: a systematic review of randomised controlled trials","volume":"53","author":"Zare","year":"2023","journal-title":"Sports Med"},{"issue":"14","key":"10.1016\/j.eprac.2025.07.017_bib210","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1080\/02640414.2020.1754716","article-title":"The effect of exercise interventions on resting metabolic rate: a systematic review and meta-analysis","volume":"38","author":"MacKenzie-Shalders","year":"2020","journal-title":"J Sports Sci"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.017_bib211","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/oby.23374","article-title":"Beyond appetite regulation: targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss","volume":"30","author":"Christoffersen","year":"2022","journal-title":"Obesity (Silver Spring)"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.017_bib212","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1249\/MSS.0000000000001448","article-title":"Associations of muscle mass and strength with all-cause mortality among US older adults","volume":"50","author":"Li","year":"2018","journal-title":"Med Sci Sports Exerc"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.017_bib213","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3390\/nu10040423","article-title":"Resistance training prevents muscle loss induced by caloric restriction in obese elderly individuals: a systematic review and meta-analysis","volume":"10","author":"Sardeli","year":"2018","journal-title":"Nutrients"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.017_bib214","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13428","article-title":"Resistance training effectiveness on body composition and body weight outcomes in individuals with overweight and obesity across the lifespan: a systematic review and meta-analysis","volume":"23","author":"Lopez","year":"2022","journal-title":"Obes Rev"},{"issue":"6","key":"10.1016\/j.eprac.2025.07.017_bib215","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1136\/bjsports-2017-098970","article-title":"Effects of short-term, medium-term and long-term resistance exercise training on cardiometabolic health outcomes in adults: systematic review with meta-analysis","volume":"54","author":"Ashton","year":"2020","journal-title":"Br J Sports Med"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.017_bib216","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jphys.2020.09.009","article-title":"Resistance training leads to large improvements in strength and moderate improvements in physical function in adults who are overweight or obese: a systematic review","volume":"66","author":"Orange","year":"2020","journal-title":"J Physiother"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.017_bib217","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13370","article-title":"The magnitude and progress of lean body mass, fat-free mass, and skeletal muscle mass loss following bariatric surgery: a systematic review and meta-analysis","volume":"23","author":"Nuijten","year":"2022","journal-title":"Obes Rev"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.017_bib218","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s00421-022-04896-5","article-title":"Lean mass sparing in resistance-trained athletes during caloric restriction: the role of resistance training volume","volume":"122","author":"Roth","year":"2022","journal-title":"Eur J Appl Physiol"},{"issue":"10","key":"10.1016\/j.eprac.2025.07.017_bib219","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1007\/s11695-020-04837-1","article-title":"Resistance training in post-metabolic and bariatric surgery patients: a systematic review","volume":"30","author":"Morales-Marroquin","year":"2020","journal-title":"Obes Surg"},{"key":"10.1016\/j.eprac.2025.07.017_bib221","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.smrv.2019.02.002","article-title":"Effects of sleep restriction on metabolism-related parameters in healthy adults: a comprehensive review and meta-analysis of randomized controlled trials","volume":"45","author":"Zhu","year":"2019","journal-title":"Sleep Med Rev"},{"issue":"11","key":"10.1016\/j.eprac.2025.07.017_bib222","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13051","article-title":"Associations of short sleep duration with appetite-regulating hormones and adipokines: a systematic review and meta-analysis","volume":"21","author":"Lin","year":"2020","journal-title":"Obes Rev"},{"issue":"12","key":"10.1016\/j.eprac.2025.07.017_bib223","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.sleep.2014.07.018","article-title":"Sleep duration and obesity among adults: a meta-analysis of prospective studies","volume":"15","author":"Wu","year":"2014","journal-title":"Sleep Med"},{"issue":"11","key":"10.1016\/j.eprac.2025.07.017_bib224","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/obr.12444","article-title":"Sleep quality and obesity in young subjects: a meta-analysis","volume":"17","author":"Fatima","year":"2016","journal-title":"Obes Rev"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.017_bib225","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.orcp.2020.03.004","article-title":"Sleep duration and obesity in adulthood: an updated systematic review and meta-analysis","volume":"14","author":"Bacaro","year":"2020","journal-title":"Obes Res Clin Pract"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.017_bib226","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41574-022-00747-7","article-title":"The role of insufficient sleep and circadian misalignment in obesity","volume":"19","author":"Chaput","year":"2023","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.017_bib227","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S2213-2600(19)30449-7","article-title":"Time to wake the giant of obstructive sleep apnoea","volume":"8","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.017_bib228","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1378\/chest.15-1010","article-title":"The weighty issue of obesity management in sleep apnea","volume":"148","author":"Patel","year":"2015","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.eprac.2025.07.017_bib229","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.2337\/dc08-1776","article-title":"Obstructive sleep apnea among obese patients with type 2 diabetes","volume":"32","author":"Foster","year":"2009","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.eprac.2025.07.017_bib230","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1513\/AnnalsATS.202101-060OC","article-title":"Effect of continuous positive airway pressure on weight and local adiposity in adults with obstructive sleep apnea: a meta-analysis","volume":"18","author":"Chen","year":"2021","journal-title":"Ann Am Thorac Soc"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.017_bib231","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1136\/thoraxjnl-2014-205361","article-title":"Effects of CPAP on body weight in patients with obstructive sleep apnoea: a meta-analysis of randomised trials","volume":"70","author":"Drager","year":"2015","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.017_bib232","doi-asserted-by":"crossref","first-page":"479","DOI":"10.5664\/jcsm.6506","article-title":"Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American Academy of Sleep Medicine clinical practice guideline","volume":"13","author":"Kapur","year":"2017","journal-title":"J Clin Sleep Med"},{"issue":"10","key":"10.1016\/j.eprac.2025.07.017_bib233","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13606","article-title":"Weight stigma experienced by patients with obesity in healthcare settings: a qualitative evidence synthesis","volume":"24","author":"Ryan","year":"2023","journal-title":"Obes Rev"},{"key":"10.1016\/j.eprac.2025.07.017_bib234","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2050-2974-1-3","article-title":"Health and health-related quality of life among treatment-seeking overweight and obese adults: associations with internalized weight bias","volume":"1","author":"Latner","year":"2013","journal-title":"J Eat Disord"},{"issue":"8","key":"10.1016\/j.eprac.2025.07.017_bib235","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/obr.12701","article-title":"Weight bias internalization and health: a systematic review","volume":"19","author":"Pearl","year":"2018","journal-title":"Obes Rev"},{"issue":"Suppl 2","key":"10.1016\/j.eprac.2025.07.017_bib236","first-page":"S80","article-title":"Understanding self-directed stigma: development of the weight bias internalization scale","volume":"16","author":"Durso","year":"2008","journal-title":"Obesity (Silver Spring)"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.017_bib237","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/oby.2009.353","article-title":"Measuring weight self-stigma: the weight self-stigma questionnaire","volume":"18","author":"Lillis","year":"2010","journal-title":"Obesity (Silver Spring)"},{"issue":"8","key":"10.1016\/j.eprac.2025.07.017_bib238","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1002\/oby.23802","article-title":"Weight discrimination, BMI, or weight bias internalization? Testing the best predictor of psychological distress and body dissatisfaction","volume":"31","author":"Macho","year":"2023","journal-title":"Obesity (Silver Spring)"},{"issue":"10","key":"10.1016\/j.eprac.2025.07.017_bib239","article-title":"Patient-centered care and \u201cpeople-first language\u201d as tools to prevent stigmatization of patients with obesity","volume":"132","author":"B\u0105k-Sosnowska","year":"2022","journal-title":"Pol Arch Intern Med"},{"key":"10.1016\/j.eprac.2025.07.017_bib240","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13030-020-00177-9","article-title":"Personalized cognitive-behavioural therapy for obesity (CBT-OB): theory, strategies and procedures","volume":"14","author":"Dalle Grave","year":"2020","journal-title":"Biopsychosoc Med"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.017_bib241","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1001\/jama.2015.18118","article-title":"Mental health conditions among patients seeking and undergoing bariatric surgery: a meta-analysis","volume":"315","author":"Dawes","year":"2016","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.017_bib242","doi-asserted-by":"crossref","first-page":"318","DOI":"10.7861\/clinmed.2023-0146","article-title":"Psychological considerations for the holistic management of obesity","volume":"23","author":"Dandgey","year":"2023","journal-title":"Clin Med (Lond)"},{"issue":"8","key":"10.1016\/j.eprac.2025.07.017_bib243","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.2337\/dc24-0491","article-title":"Effect of semaglutide on regression and progression of glycemia in people with overweight or obesity but without diabetes in the SELECT trial","volume":"47","author":"Kahn","year":"2024","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.eprac.2025.07.017_bib244","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for obesity treatment and diabetes prevention","volume":"392","author":"Jastreboff","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.017_bib245","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients","volume":"27","author":"Torgerson","year":"2004","journal-title":"Diabetes Care"},{"issue":"10402","key":"10.1016\/j.eprac.2025.07.017_bib246","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"issue":"10278","key":"10.1016\/j.eprac.2025.07.017_bib247","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.017_bib248","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2337\/dc19-1745","article-title":"Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: The SCALE insulin randomized controlled trial","volume":"43","author":"Garvey","year":"2020","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2025.07.017_bib249","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.2337\/diacare.21.8.1288","article-title":"Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study","volume":"21","author":"Hollander","year":"1998","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.eprac.2025.07.017_bib250","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.2337\/dc13-0234","article-title":"Effects of naltrexone sustained-release\/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes","volume":"36","author":"Hollander","year":"2013","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.017_bib251","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis","volume":"28","author":"Sattar","year":"2022","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.017_bib252","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.017_bib253","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11906-019-0915-1","article-title":"Weight loss medications in the treatment of obesity and hypertension","volume":"21","author":"Cohen","year":"2019","journal-title":"Curr Hypertens Rep"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.017_bib254","article-title":"Long-term effects of weight-reducing drugs in people with hypertension","volume":"1","author":"Siebenhofer","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.017_bib255","doi-asserted-by":"crossref","first-page":"772","DOI":"10.3390\/jcm12030772","article-title":"The effect of semaglutide on blood pressure in patients without diabetes: a systematic review and meta-analysis","volume":"12","author":"Kennedy","year":"2023","journal-title":"J Clin Med"},{"issue":"38","key":"10.1016\/j.eprac.2025.07.017_bib256","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1093\/eurheartj\/ehae564","article-title":"Semaglutide and blood pressure: an individual patient data meta-analysis","volume":"45","author":"Kennedy","year":"2024","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.eprac.2025.07.017_bib257","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1111\/dom.15272","article-title":"Effect of tirzepatide on blood pressure and lipids: a meta-analysis of randomized controlled trials","volume":"25","author":"Kanbay","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.017_bib258","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1161\/HYPERTENSIONAHA.123.22022","article-title":"Tirzepatide reduces 24-hour ambulatory blood pressure in adults with body mass index \u226527 kg\/m(2): SURMOUNT-1 ambulatory blood pressure monitoring substudy","volume":"81","author":"de Lemos","year":"2024","journal-title":"Hypertension"},{"issue":"19","key":"10.1016\/j.eprac.2025.07.017_bib259","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1136\/heartjnl-2024-324170","article-title":"Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial","volume":"110","author":"Krumholz","year":"2024","journal-title":"Heart"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.017_bib260","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3945\/ajcn.111.024927","article-title":"Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study","volume":"95","author":"Garvey","year":"2012","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.017_bib261","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12902-018-0332-5","article-title":"Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials","volume":"19","author":"Zhao","year":"2019","journal-title":"BMC Endocr Disord"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.017_bib262","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jash.2017.12.002","article-title":"Effects of orlistat on blood pressure: a systematic review and meta-analysis of 27 randomized controlled clinical trials","volume":"12","author":"Sahebkar","year":"2018","journal-title":"J Am Soc Hypertens"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.017_bib263","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.eprac.2025.07.017_bib264","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.eprac.2025.07.017_bib265","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.017_bib266","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.eprac.2025.07.017_bib267","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.eprac.2025.07.017_bib268","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1056\/NEJMoa2403664","article-title":"Once-weekly semaglutide in persons with obesity and knee osteoarthritis","volume":"391","author":"Bliddal","year":"2024","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.eprac.2025.07.017_bib269","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.017_bib270","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s13679-024-00592-x","article-title":"Estimating cardiovascular benefits of tirzepatide in sleep apnea and obesity: insight from the SURMOUNT-OSA trials","volume":"13","author":"Beccuti","year":"2024","journal-title":"Curr Obes Rep"},{"issue":"8","key":"10.1016\/j.eprac.2025.07.017_bib271","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/ijo.2016.52","article-title":"Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial","volume":"40","author":"Blackman","year":"2016","journal-title":"Int J Obes (Lond)"},{"issue":"1722","key":"10.1016\/j.eprac.2025.07.017_bib272","doi-asserted-by":"crossref","first-page":"29","DOI":"10.58347\/tml.2025.1722c","article-title":"Tirzepatide (Zepbound) for obstructive sleep apnea","volume":"67","year":"2025","journal-title":"Med Lett Drugs Ther"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.017_bib273","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.eprac.2020.10.005","article-title":"Binge-eating disorder and type 2 diabetes: a review","volume":"27","author":"Harris","year":"2021","journal-title":"Endocr Pract"},{"issue":"11","key":"10.1016\/j.eprac.2025.07.017_bib274","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1002\/oby.23898","article-title":"Naltrexone\/bupropion for binge-eating disorder: a randomized, double-blind, placebo-controlled trial","volume":"31","author":"Grilo","year":"2023","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.017_bib275","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s10194-023-01671-5","article-title":"European Headache Federation (EHF) critical reappraisal and meta-analysis of oral drugs in migraine prevention \u2013 part 3: topiramate","volume":"24","author":"Raffaelli","year":"2023","journal-title":"J Headache Pain"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.017_bib276","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/add.15572","article-title":"Effect of extended-release naltrexone on alcohol consumption: a systematic review and meta-analysis","volume":"117","author":"Murphy","year":"2022","journal-title":"Addiction"},{"issue":"9","key":"10.1016\/j.eprac.2025.07.017_bib277","article-title":"Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses","volume":"9","author":"Lindson","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.017_bib278","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1080\/21556660.2019.1678478","article-title":"The effectiveness and safety of pharmaceuticals to manage excess weight post-bariatric surgery: a systematic literature review","volume":"8","author":"Wharton","year":"2019","journal-title":"J Drug Assess"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.017_bib279","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1210\/clinem\/dgaa702","article-title":"Approach to the patient: management of the post\u2013bariatric surgery patient with weight regain","volume":"106","author":"Istfan","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.eprac.2025.07.017_bib280","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3949\/ccjm.91a.24068","article-title":"Effective but inaccessible antiobesity medications: a call for sharing responsibility for improving access to evidence-based care","volume":"91","author":"Burguera","year":"2024","journal-title":"Cleve Clin J Med"},{"issue":"7","key":"10.1016\/j.eprac.2025.07.017_bib281","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/j.1552-4604.1996.tb04230.x","article-title":"The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers","volume":"36","author":"Melia","year":"1996","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.eprac.2025.07.017_bib282","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1592\/phco.22.11.814.33627","article-title":"Effects of orlistat on fat-soluble vitamins in obese adolescents","volume":"22","author":"McDuffie","year":"2002","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.017_bib283","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.diabet.2015.08.006","article-title":"Weight loss at a high cost: orlistat-induced late-onset severe kidney disease","volume":"42","author":"Buysschaert","year":"2016","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.eprac.2025.07.017_bib284","series-title":"Roche Pharmaceuticals","author":"Nutley","year":"2009"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.017_bib285","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1210\/clinem\/dgaa702","article-title":"Approach to the patient: management of the post-bariatric surgery patient with weight regain","volume":"106","author":"Istfan","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.017_bib286","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2022.08.045","article-title":"AGA clinical practice guideline on pharmacological interventions for adults with obesity","volume":"163","author":"Grunvald","year":"2022","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.017_bib287","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1210\/jc.2014-3421","article-title":"Clinical review: drugs commonly associated with weight change: a systematic review and meta-analysis","volume":"100","author":"Domecq","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.eprac.2025.07.017_bib288","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/oby.21136","article-title":"Treatment of obesity: pharmacotherapy trends in the United States from 1999 to 2010","volume":"23","author":"Xia","year":"2015","journal-title":"Obesity (Silver Spring)"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.017_bib289","doi-asserted-by":"crossref","first-page":"380","DOI":"10.7326\/0003-4819-143-5-200509060-00013","article-title":"Anorectics on trial: a half century of federal regulation of prescription appetite suppressants","volume":"143","author":"Colman","year":"2005","journal-title":"Ann Intern Med"},{"issue":"5588","key":"10.1016\/j.eprac.2025.07.017_bib290","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1136\/bmj.1.5588.352","article-title":"Comparison of continuous and intermittent anorectic therapy in obesity","volume":"1","author":"Munro","year":"1968","journal-title":"Br Med J"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.017_bib292","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/oby.22430","article-title":"Safety and effectiveness of longer-term phentermine use: clinical outcomes from an electronic health record cohort","volume":"27","author":"Lewis","year":"2019","journal-title":"Obesity (Silver Spring)"},{"issue":"10","key":"10.1016\/j.eprac.2025.07.017_bib293","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/j.1463-1326.2010.01242.x","article-title":"Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity","volume":"12","author":"Kang","year":"2010","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.eprac.2025.07.017_bib294","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1038\/oby.2011.94","article-title":"Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity","volume":"19","author":"Hendricks","year":"2011","journal-title":"Obesity (Silver Spring)"},{"issue":"11","key":"10.1016\/j.eprac.2025.07.017_bib295","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/oby.20584","article-title":"Evaluation of phentermine and topiramate versus phentermine\/topiramate extended-release in obese adults","volume":"21","author":"Aronne","year":"2013","journal-title":"Obesity (Silver Spring)"},{"issue":"11","key":"10.1016\/j.eprac.2025.07.017_bib296","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1002\/oby.23548","article-title":"The use of virtual visits for obesity pharmacotherapy in patients with overweight or obesity compared with in-person encounters","volume":"30","author":"Griebeler","year":"2022","journal-title":"Obesity (Silver Spring)"},{"issue":"6","key":"10.1016\/j.eprac.2025.07.017_bib297","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200014","article-title":"Phentermine\/topiramate for the treatment of adolescent obesity","volume":"1","author":"Kelly","year":"2022","journal-title":"NEJM Evid"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.017_bib298","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/14740338.2017.1247807","article-title":"Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone\/bupropion extended release and phentermine-topiramate extended release","volume":"16","author":"Halpern","year":"2017","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.017_bib299","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/oby.2011.330","article-title":"Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP)","volume":"20","author":"Allison","year":"2012","journal-title":"Obesity (Silver Spring)"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.017_bib300","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1210\/jc.2018-01010","article-title":"Cardiovascular safety during and after use of phentermine and topiramate","volume":"104","author":"Ritchey","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2025.07.017_bib301","series-title":"Contrave (naltrexone hydrochloride and bupropion hydrochloride) extended-release tablets, for oral use [package insert]","year":"2025"},{"key":"10.1016\/j.eprac.2025.07.017_bib302","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2014.04.004","article-title":"Naltrexone\/bupropion for obesity: an investigational combination pharmacotherapy for weight loss","volume":"84","author":"Billes","year":"2014","journal-title":"Pharmacol Res"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.017_bib303","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/oby.20309","article-title":"A randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II)","volume":"21","author":"Apovian","year":"2013","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.017_bib304","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/oby.2010.147","article-title":"Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial","volume":"19","author":"Wadden","year":"2011","journal-title":"Obesity (Silver Spring)"},{"issue":"9","key":"10.1016\/j.eprac.2025.07.017_bib305","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/ijo.2016.67","article-title":"The relationship between early weight loss and weight loss at 1 year with naltrexone ER\/bupropion ER combination therapy","volume":"40","author":"Fujioka","year":"2016","journal-title":"Int J Obes (Lond)"},{"issue":"10","key":"10.1016\/j.eprac.2025.07.017_bib306","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1001\/jama.2016.1558","article-title":"Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.eprac.2025.07.017_bib307","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101090","article-title":"Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease","volume":"46","author":"Baggio","year":"2021","journal-title":"Mol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2025.07.017_bib308","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.eprac.2025.07.017_bib309","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol Metab"},{"key":"10.1016\/j.eprac.2025.07.017_bib310","series-title":"Saxenda (liraglutide) [package insert]","year":"2020"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.017_bib311","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.eprac.2025.07.017_bib312","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1002\/oby.21629","article-title":"Early weight loss with liraglutide 3.0 mg predicts 1-year weight loss and is associated with improvements in clinical markers","volume":"24","author":"Fujioka","year":"2016","journal-title":"Obesity (Silver Spring, Md)"},{"issue":"24","key":"10.1016\/j.eprac.2025.07.017_bib313","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-weekly semaglutide in adolescents with obesity","volume":"387","author":"Weghuber","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.017_bib314","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.017_bib315","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial","volume":"5","author":"Ahr\u00e9n","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.017_bib316","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial","volume":"41","author":"Ahmann","year":"2018","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.017_bib317","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"Aroda","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.eprac.2025.07.017_bib318","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1210\/jc.2018-00070","article-title":"Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial","volume":"103","author":"Rodbard","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.eprac.2025.07.017_bib319","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes","volume":"42","author":"Aroda","year":"2019","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.eprac.2025.07.017_bib320","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.2337\/dc19-0883","article-title":"Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial","volume":"42","author":"Rodbard","year":"2019","journal-title":"Diabetes Care"},{"issue":"15","key":"10.1016\/j.eprac.2025.07.017_bib321","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/jama.2019.2942","article-title":"Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"issue":"10192","key":"10.1016\/j.eprac.2025.07.017_bib322","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial","volume":"394","author":"Pratley","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.eprac.2025.07.017_bib323","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S2213-8587(19)30192-5","article-title":"Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.eprac.2025.07.017_bib324","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S2213-8587(19)30194-9","article-title":"Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial","volume":"7","author":"Pieber","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"10.1016\/j.eprac.2025.07.017_bib325","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.2337\/dc19-0898","article-title":"Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial","volume":"42","author":"Zinman","year":"2019","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.017_bib326","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S2213-8587(20)30075-9","article-title":"Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2\/3a, randomised, controlled trial","volume":"8","author":"Yamada","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.017_bib327","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S2213-8587(20)30074-7","article-title":"Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial","volume":"8","author":"Yabe","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.eprac.2025.07.017_bib328","series-title":"Wegovy (semaglutide) injection, for subcutaneous use","year":"2024"},{"issue":"10","key":"10.1016\/j.eprac.2025.07.017_bib330","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"issue":"10403","key":"10.1016\/j.eprac.2025.07.017_bib331","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.eprac.2025.07.017_bib332","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.eprac.2025.07.017_bib333","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S2213-8587(21)00174-1","article-title":"Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial","volume":"9","author":"Fr\u00edas","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"19","key":"10.1016\/j.eprac.2025.07.017_bib334","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.eprac.2025.07.017_bib335","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.2337\/dc21-1785","article-title":"Changes in glucose metabolism and glycemic status with once-weekly subcutaneous semaglutide 2.4 mg among participants with prediabetes in the STEP program","volume":"45","author":"Perreault","year":"2022","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2025.07.017_bib338","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/s41366-023-01321-5","article-title":"Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis","volume":"47","author":"Tan","year":"2023","journal-title":"Int J Obes (Lond)"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.017_bib339","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.eprac.2025.07.017_bib340","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"issue":"10300","key":"10.1016\/j.eprac.2025.07.017_bib341","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"issue":"10313","key":"10.1016\/j.eprac.2025.07.017_bib342","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.eprac.2025.07.017_bib343","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of Subcutaneous Tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA"},{"issue":"10295","key":"10.1016\/j.eprac.2025.07.017_bib344","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.eprac.2025.07.017_bib346","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2023.09.007","article-title":"Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics","volume":"267","author":"Nicholls","year":"2024","journal-title":"Am Heart J"},{"key":"10.1016\/j.eprac.2025.07.017_bib347","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.amjcard.2022.07.003","article-title":"Updated meta-analysis assessing the cardiovascular efficacy of tirzepatide","volume":"181","author":"Patoulias","year":"2022","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.017_bib349","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2025.103238","article-title":"Glucagon-like peptide-1 receptor agonists, dual GIP\/GLP-1 receptor agonist tirzepatide and suicidal ideation and behavior: a systematic review of clinical studies and pharmacovigilance reports","volume":"19","author":"Di Stefano","year":"2025","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.eprac.2025.07.017_bib350","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jad.2024.10.062","article-title":"Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: a replication study using reports to the World Health Organization pharmacovigilance database (VigiBase\u00ae)","volume":"369","author":"McIntyre","year":"2025","journal-title":"J Affect Disord"},{"key":"10.1016\/j.eprac.2025.07.017_bib351","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jpsychires.2025.02.008","article-title":"The effect of glucagon-like peptide-1 receptor agonists on measures of suicidality: a systematic review","volume":"183","author":"Valentino","year":"2025","journal-title":"J Psychiatr Res"},{"issue":"11","key":"10.1016\/j.eprac.2025.07.017_bib352","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1111\/dom.14133","article-title":"Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome","volume":"22","author":"Haws","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.eprac.2025.07.017_bib353","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S2213-8587(20)30366-1","article-title":"Setmelanotide: what does it mean for clinical care of patients with obesity?","volume":"8","author":"Ryan","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.017_bib354","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40265-021-01470-9","article-title":"Setmelanotide: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.eprac.2025.07.017_bib355","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S2213-8587(20)30364-8","article-title":"Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials","volume":"8","author":"Cl\u00e9ment","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"10.1016\/j.eprac.2025.07.017_bib356","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S2213-8587(22)00277-7","article-title":"Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alstr\u00f6m syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period","volume":"10","author":"Haqq","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.eprac.2025.07.017_bib357","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S2213-8587(24)00087-1","article-title":"Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial","volume":"12","author":"Roth","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.017_bib358","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/oby.22347","article-title":"A randomized, double-blind, placebo-controlled study of Gelesis100: a novel nonsystemic oral hydrogel for weight loss","volume":"27","author":"Greenway","year":"2019","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.eprac.2025.07.017_bib359","article-title":"Weight and cardiometabolic effects of a novel oral shape-shifting superabsorbent hydrogel capsule: prespecified and exploratory analysis of the Epitomee capsule RESET study","volume":"13","author":"Bays","year":"2025","journal-title":"Obes Pillars"},{"issue":"10","key":"10.1016\/j.eprac.2025.07.017_bib361","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s11095-024-03771-6","article-title":"Impact of manufacturing process and compounding on properties and quality of follow-on GLP-1 polypeptide drugs","volume":"41","author":"Hach","year":"2024","journal-title":"Pharm Res"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25009772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25009772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T08:06:34Z","timestamp":1768464394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X25009772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":350,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1530891X25009772"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2025.07.017","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"American Association of Clinical Endocrinology Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity\/Adiposity-Based Chronic Disease \u2013 2025 Update","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2025.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}